Aligos Therapeutics (ALGS)
(Real Time Quote from BATS)
$7.94 USD
+0.03 (0.38%)
Updated Aug 6, 2025 10:56 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ALGS 7.94 +0.03(0.38%)
Will ALGS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALGS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALGS
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates
Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Lags Revenue Estimates
ALGS: What are Zacks experts saying now?
Zacks Private Portfolio Services
UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates
PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last?
Other News for ALGS
Earnings Scheduled For August 6, 2025
Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025 | ALGS ...
Aligos Therapeutics (ALGS) Grants Stock Options to New Employees | ALGS Stock News
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ALGS ...
Aligos Therapeutics announces inducement grants under Nasdaq listing rule